Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib and Lanraplenib in Cutaneous Lupus Erythematosus
NCT03134222Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of filgotinib, lanraplenib in cutaneous lupus erythematosus (CLE), sponsored by Gilead Sciences. Started May 2017; status: completed.
02
Drugs
filgotiniblanraplenib
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT03134222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03134222.